Sucampo Pharmaceuticals, Inc. – Product Pipeline Review – H2 2011 by GlobalMarketsDirect

VIEWS: 5 PAGES: 62

More Info
									      Sucampo Pharmaceuticals, Inc. – Product Pipeline
                   Review – H2 2011
                                                                                          Reference Code: GMDHC01420CDB

                                                                                                 Publication Date: OCT 2011




Sucampo Pharmaceuticals, Inc. – Product Pipeline Review – H2 2011                           GMDHC01420CDB / Published OCT 2011

© Global Markets Direct. This report is a licensed product and is not to be photocopied                                 Page(1)
Sucampo Pharmaceuticals, Inc. – Product Pipeline Review




Ta b le o f Co n te n ts
Table of Contents ..................................................................................................................................................................................................... 2
      List of Tables...................................................................................................................................................................................................... 4
      List of Figures .................................................................................................................................................................................................... 5
Sucampo Pharmaceuticals, Inc. Snapshot................................................................................................................................................................ 6
      Sucampo Pharmaceuticals, Inc. Overview ......................................................................................................................................................... 6
      Key Information .................................................................................................................................................................................................. 6
      Key Facts ........................................................................................................................................................................................................... 6
Sucampo Pharmaceuticals, Inc. – Research and Development Overview ................................................................................................................ 7
      Key Therapeutic Areas ....................................................................................................................................................................................... 7
Sucampo Pharmaceuticals, Inc. – Pipeline Review................................................................................................................................................... 9
      Pipeline Products by Stage of Development ....................................................................................................................................................... 9
      Pipeline Products – Monotherapy .....................................................................................................................................................................10
Sucampo Pharmaceuticals, Inc. – Pipeline Products Glance ...................................................................................................................................11
      Sucampo Pharmaceuticals, Inc. – Late Stage Pipeline ......................................................................................................................................11
            Phase III Products/Combination Treatment Modalities ................................................................................................................................11
      Sucampo Pharmaceuticals, Inc. Clinical Stage Pipeline Products .....................................................................................................................12
            Phase II Products/Combination Treatment Modalities .................................................................................................................................12
Sucampo Pharmaceuticals, Inc. – Drug Profiles ......................................................................................................................................................13
      Amitiza ..............................................................................................................................................................................................................13
            Product Description ....................................................................................................................................................................................13
            Mechanism of Action...................................................................................................................................................................................13
            R&D Progress .............................................................................................................................................................................................13
      Rescula .............................................................................................................................................................................................................15
            Product Description ....................................................................................................................................................................................15
            Mechanism of Action...................................................................................................................................................................................15
            R&D Progress .............................................................................................................................................................................................15
Sucampo Pharmaceuticals, Inc. – Pipeline Analysis ................................................................................................................................................16
      Sucampo Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class .......................................................................................................16
      Sucampo Pharmaceuticals, Inc. - Pipeline Products By Target .........................................................................................................................17
      Sucampo Pharmaceuticals, Inc. – Pipeline Products by Route of Administration ...............................................................................................18
      Sucampo Pharmaceuticals, Inc. – Pipeline Products by Molecule Type ............................................................................................................19
Sucampo Pharmaceuticals, Inc. – Recent Pipeline Updates ...................................................................................................................................20
Sucampo Pharmaceuticals, Inc. – Locations And Subsidiaries ................................................................................................................................23
      Head Office .......................................................................................................................................................................................................23
Recent Developments .............................................................................................................................................................................................24
            Nov 30, 2010: Sucampo's Lubiprostone Successfully Completes Long-Term Phase III Safety Trial In Chronic Idiopathic Constipation ......24
            Apr 29, 2008: Sucampo Pharmaceuticals Obtains USFDA Approval For AMITIZA For The Treatment Of Irritable Bowel Syndrome With
            Constipation................................................................................................................................................................................................25
            Jul 28, 2008: Sucampo Pharmaceuticals Initiates Phase 2 Trial Of Cobiprostone For The Treatment Of Portal Hypertension In Patients
            With Liver Cirrhosis .....................................................................................................................................................................................26
            May 28, 2009: Sucampo Board Of Directors Issues Statement Regarding Sales Performance By Takeda Pharmaceuticals North America
            For Amitiza. ................................................................................................................................................................................................27
            May 27, 2008: AMITIZA (lubiprostone) 8 mcg Now Available to Treat Irritable Bowel Syndrome with Constipation in Adult Women ...........27
            Feb 27, 2008: Sucampo Pharmaceuticals Announces the Initiation of Filings of Marketing Authorization Applications for AMITIZA in Europe
            ...................................................................................................................................................................................................................27
            Feb 26, 2007: Takeda and TAP to Promote Sucampo's AMITIZA in the United States ...............................................................................28
            Apr 25, 2006: Amitiza (lubiprostone), the First Selective Chloride Channel Activator for the Treatment of Chronic Idiopathic Constipation,
            Launches in the United States ....................................................................................................................................................................29




Sucampo Pharmaceuticals, Inc. – Product Pipeline Review – H2 2011                                                                                              GMDHC01420CDB / Published OCT 2011

©Global Markets Direct.. This report is a licensed product and is not to be photocopied                                                                                                                                    Page(2)
Sucampo Pharmaceuticals, Inc. – Product Pipeline Review



           Oct 23, 2006: Study Demonstrated AMITIZA (Lubiprostone) Showed Efficacy Within 24 And 48 Hours Of Treatment. ...............................29
           Jul 22, 2010: R-Tech Ueno Reports Change In Storage Condition For Rescula Eye Drops 0.12%..............................................................30
           May 22, 2006: AMITIZA (lubiprostone) Shown Effective and Well-Tolerated ...............................................................................................30
           May 22, 2006: New Study Demonstrates that AMITIZA (lubiprostone) May Help Improve Symptoms of Irritable Bowel Syndrome with
           Constipation................................................................................................................................................................................................31
           Jul 21, 2009: Takeda And Sucampo Report Top-Line Results Of Two Phase 3 Trials Of Lubiprostone In Opioid-Induced Bowel Dysfunction
           ...................................................................................................................................................................................................................31
           Nov 20, 2009: Sucampo Receives Marketing Authorization For Amitiza(R) In Switzerland For Treatment Of Chronic Idiopathic Constipation
           ...................................................................................................................................................................................................................32
           Sep 20, 2007: Sucampo Pharmaceuticals Initiates Phase 2, Dose-Finding Trial Of Cobiprostone For The Prevention Of NSAID-Induced
           Ulcers In Arthritis Patients ...........................................................................................................................................................................33
           Sep 20, 2006: AMITIZA (lubiprostone) Effective in Treating Chronic Idiopathic Constipation in People Age 65 and Older ..........................33
           Sep 19, 2006: Sucampo’s AMITIZA is Finalist for The Scrip Award ............................................................................................................34
           May 19, 2009: Sucampo Initiates Pivotal Phase 3 Efficacy Trial Of Lubiprostone For Chronic Idiopathic Constipation In Japan. ................34
           Dec 18, 2008: Sucampo Initiates Phase 1 Study Of SPL-017 For Peripheral Arterial Disease ....................................................................35
           Sep 18, 2008: Sucampo Pharmaceuticals Announces Positive Results from a Japanese Phase 2b Dose-Ranging Study of AMITIZA for
           Chronic Idiopathic Constipation...................................................................................................................................................................35
           Sep 18, 2007: FDA Accepts Sucampo'S Snda For Lubiprostone (8 Mcg) For The Treatment Of Irritable Bowel Syndrome With Constipation
           (Ibs-C). .......................................................................................................................................................................................................36
           May 18, 2008: New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel
           Syndrome with Constipation (IBS-C) ...........................................................................................................................................................37
           Oct 15, 2007: Sucampo Pharmaceuticals Presents Data On Cobiprostone At American College Of Gastroenterology Annual Scientific
           Meeting.......................................................................................................................................................................................................37
           Jul 15, 2010: R-Tech Ueno Completes Phase II Clinical Study On Ophthalmic Solution UF-021 For Retinitis Pigmentosa .........................38
           Mar 14, 2007: Sucampo Pharma, Ltd Initiates Clinical Study Of AMITIZA In Japan . ..................................................................................39
           Sep 13, 2007: Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone To Treat Opioid-Induced Bowel
           Dysfunction (OBD) ......................................................................................................................................................................................39
           Mar 13, 2007: Sucampo Pharmaceuticals Initiates Post-Marketing Studies of AMITIZA in Subjects with Renal or Hepatic Impairment .......40
           Jan 13, 2011: Sucampo Initiates Third Phase III Clinical Trial Of Lubiprostone ...........................................................................................40
           Jul 12, 2007: Sucampo Pharmaceuticals Submits Supplemental New Drug Application For Lubiprostone To Treat Irritable Bowel Syndrome
           With Constipation........................................................................................................................................................................................41
           May 11, 2010: Sucampo Presents Results From Phase III Clinical Trial Of Lubiprostone For Treatment Of Opioid-Induced Bowel
           Dysfunction .................................................................................................................................................................................................41
           Jun 09, 2008: Sucampo Pharma Europe Submits Marketing Authorization Application In Switzerland. .......................................................42
           May 09, 2011: Sucampo And Abbott Report Phase III Clinical Trial Data Of Lubiprostone In Japanese Patients With Chronic Idiopathic
           Constipation At DDW 2011 .........................................................................................................................................................................42
           Jun 08, 2010: Sucampo And Abbott Successfully Complete Phase III Efficacy Trial Of Lubiprostone In Japanese Patients Suffering From
           Chronic Idiopathic Constipation...................................................................................................................................................................44
           Jan 08, 2009: Sucampo Completes Enrollment In Its Phase 2 Trial Of Cobiprostone For The Prevention Of NSAID-Induced Ulcers ..........45
           Oct 07, 2010: Sucampo Submits Marketing Application To Japanese Regulatory Authorities For Amitiza ...................................................45
           Jan 07, 2011: Sucampo And Takeda Begin Third Phase III Clinical Trial Of Lubiprostone In Opioid-Induced Bowel Dysfunction ................46
           Nov 06, 2007: “Move to AMITIZA” Advertising Campaign Underscores the Power of Not Letting Chronic Constipation Slow People Down 46
           May 06, 2010: R-Tech Ueno's Sanda Factory Gets U.S. Nod for Manufacture of Rescula Eye Drops. ........................................................47
           Sep 04, 2009: Sucampo Withdraws European Marketing Application For Lubiprostone. .............................................................................48
           May 04, 2011: Sucampo Presents Phase II Clinical Trial Data Of UF-021 In Retinitis Pigmentosa Patients At A
								
To top